---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-267487"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2026-06-11T20:05:16+00:00"
generated_at: "2026-06-11T20:11:59.794997+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics reports 2026 annual meeting voting results

## Summary
- At June 10, 2026 annual meeting, 877,358 of 1,921,567 outstanding shares represented.
- Directors William P. Quinn and Jakob Dupont elected as Class II members for three-year terms.
- Quinn: 349,358 for, 52,117 withheld; Dupont: 377,163 for, 24,312 withheld; 475,883 broker non-votes each.
- Ratification of PricewaterhouseCoopers as auditor for 2026: 768,336 for, 107,471 against, 1,551 abstain.

## SEC filing metadata
- accession: 0001193125-26-267487
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2026-06-11T20:05:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/0001193125-26-267487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/bolt-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-267487
- JSON: https://secwatch.observer/filing/0001193125-26-267487.json
- Plain text: https://secwatch.observer/filing/0001193125-26-267487.txt

## Key facts
- Shareholder Votes
  Bolt Biotherapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: The following director nominees were elected to serve as Class II members of the Company’s board of directors until the Company’s 2029 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/0001193125-26-267487-index.htm
- Shareholder Votes
  Bolt Biotherapeutics, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 at the 2026-06-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/0001193125-26-267487-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.